COP vs PFE: Which Is the Better Buy?
Side-by-side comparison of ConocoPhillips and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-22.
ConocoPhillips · Energy
$127.53
+32.1% upside to fair value
Med Conviction
Grade B
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
COP has more upside to fair value
(+32.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
COP |
PFE |
| Current Price |
$127.53 |
$27.64 |
| Fair Value Estimate |
$168.50 |
$30.94 |
| Upside to Fair Value |
+32.1%
|
+12.0%
|
| Market Cap |
$155.4B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
6.2x
|
17.4x
|
| Price / Sales |
2.5x
|
2.5x
|
| Price / FCF |
7.9x
|
14.3x
|
| Revenue Growth YoY |
+36.8%
|
+2.6%
|
| Gross Margin |
27.7%
|
71.3%
|
| Operating Margin |
21.9%
|
25.1%
|
| Return on Equity |
14.3%
|
4.9%
|
| Dividend Yield |
2.63% |
6.22% |
| FCF Yield |
12.66%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
ConocoPhillips is a global exploration and production company with a portfolio spanning unconventional North American shale, conventional international assets, LNG ventures, and Canadian oil sands, run by a new leadership team after Andy O'Brien became CEO on September 1, 2026. The business quality is medium: it generates substantial cash, with $16.15 in free cash flow per share and a 14.3% retur…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
COP |
PFE |
| Zone Low |
$126.38 |
$23.21 |
| Zone High |
$143.22 |
$26.30 |
| In Buy Zone? |
Yes
|
No
|